An expanding therapeutic pipeline.

Our commercial allografts are the first expression of Britecyte’s platform. The same native adipose biology is now being advanced—carefully, and through staged development—into programs where tissue restoration may address serious unmet need.

Clinical development

BRC-OA for knee osteoarthritis

Osteoarthritis remains a leading cause of adult disability, with current options largely limited to temporary symptom relief. BRC-OA is Britecyte’s investigational human adipose allograft program for knee OA—designed as an off-the-shelf approach that does not require harvesting a patient’s own fat for each treatment.

FDA Safe to Proceed status; IND cleared to initiate Phase 1/2a
Phase 1/2a multicenter dose-finding study underway
$1M MSCRF Clinical Program Grant support

Late preclinical

Adipose therapy for MASH

Metabolic dysfunction–associated steatohepatitis (MASH) is driven in part by disrupted metabolism in adipose tissue. Britecyte is developing an engineered adipose-based approach aimed at that underlying biology, advancing through rigorous preclinical evaluation before any clinical path.

MSCRF Commercialization Grant–supported program
Late-stage preclinical development reached with published results
Formulation and regimen optimization ongoing

Programs described here are investigational and not available for commercial use. Development status reflects publicly disclosed milestones and may change as research continues.

← Back to products Britecyte platform